| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
MAVS Blocking Peptide for STJ501720 is synthetically produced from the 500-540 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
MAVS |
| Gene ID: |
57506 |
| Uniprot ID: |
MAVS_HUMAN |
| Immunogen Region: |
500-540 |
| Specificity: |
This blocking peptide is recommended for use in combination with MAVS antibody, STJ501720 |
| Immunogen: |
Synthetic peptide taken within amino acid region 500-540 on on human mitochondrial antiviral-signaling protein isoform 1. |
| Tissue Specificity | Present in T-cells, monocytes, epithelial cells and hepatocytes (at protein level). Ubiquitously expressed, with highest levels in heart, skeletal muscle, liver, placenta and peripheral blood leukocytes. |
| Post Translational Modifications | Following activation, phosphorylated by TBK1 at Ser-442 in the pLxIS motif. The phosphorylated pLxIS motif constitutes an IRF3-binding motif, leading to recruitment of the transcription factor IRF3 to induce type-I interferons and other cytokines. Ubiquitinated. Undergoes 'Lys-48'-linked polyubiquitination catalyzed by ITCH.ITCH-dependent polyubiquitination is mediated by the interaction with PCBP2 and leads to MAVS/IPS1 proteasomal degradation. Ubiquitinated by RNF125, leading to its degradation by the proteasome. Undergoes 'Lys-48'-linked ubiquitination catalyzed by SMURF1. Ubiquitinated via 'Lys-63'-linked ubiquitination at Lys-10, Lys-311 and Lys-461 by TRIM31, promoting MAVS polymerization and formation of three-stranded helical filaments on mitochondria. Undergoes 'Lys-63'-linked ubiquitination leading to enhanced interaction between MAVS and TRAF2. Undergoes 'Lys-27'-linked ubiquitination by TRIM21 leading to enhanced interaction between MAVS and TBK1. Proteolytically cleaved by apoptotic caspases during apoptosis, leading to its inactivation. Cleavage by CASP3 during virus-induced apoptosis inactivates it, preventing cytokine overproduction. (Microbial infection) Cleaved and degraded by hepatitis A virus (HAV) protein 3ABC allowing the virus to disrupt the activation of host IRF3 through the MDA5 pathway. (Microbial infection) Cleaved by the protease 2A of coxsackievirus B3, poliovirus and enterovirus 71 allowing the virus to disrupt the host type I interferon production. (Microbial infection) Cleaved by Seneca Valley virus protease 3C allowing the virus to suppress interferon type-I production. (Microbial infection) Cleaved by HCV protease NS3/4A, thereby preventing the establishment of an antiviral state. (Microbial infection) UFMylated by ULF1 in association with Epstein-Barr virus BILF1.leading to MAVS routing to the lysosome. |
| Function | Adapter required for innate immune defense against viruses. Acts downstream of DHX33, RIGI and IFIH1/MDA5, which detect intracellular dsRNA produced during viral replication, to coordinate pathways leading to the activation of NF-kappa-B, IRF3 and IRF7, and to the subsequent induction of antiviral cytokines such as IFNB and RANTES (CCL5). Peroxisomal and mitochondrial MAVS act sequentially to create an antiviral cellular state. Upon viral infection, peroxisomal MAVS induces the rapid interferon-independent expression of defense factors that provide short-term protection, whereas mitochondrial MAVS activates an interferon-dependent signaling pathway with delayed kinetics, which amplifies and stabilizes the antiviral response. May activate the same pathways following detection of extracellular dsRNA by TLR3. May protect cells from apoptosis. Involved in NLRP3 inflammasome activation by mediating NLRP3 recruitment to mitochondria. |
| Peptide Name | Mitochondrial Antiviral-Signaling ProteinMavsCard Adapter Inducing Interferon BetaCardifInterferon Beta Promoter Stimulator Protein 1Ips-1Putative Nf-Kappa-B-Activating Protein 031nVirus-Induced-Signaling AdapterVisa |
| Database Links | Reactome: R-HSA-168928Reactome: R-HSA-5689896Reactome: R-HSA-918233Reactome: R-HSA-933541Reactome: R-HSA-933542Reactome: R-HSA-933543Reactome: R-HSA-936440Reactome: R-HSA-9692916Reactome: R-HSA-9705671 |
| Cellular Localisation | Mitochondrion Outer MembraneSingle-Pass Membrane ProteinMitochondrionPeroxisome |
| Alternative Peptide Names | Mitochondrial Antiviral-Signaling Protein proteinMavs proteinCard Adapter Inducing Interferon Beta proteinCardif proteinInterferon Beta Promoter Stimulator Protein 1 proteinIps-1 proteinPutative Nf-Kappa-B-Activating Protein 031n proteinVirus-Induced-Signaling Adapter proteinVisa proteinMAVS proteinIPS1 proteinKIAA1271 proteinVISA protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
